Reports Q4 revenue EUR 1.48B vs. EUR 4.28B last year. “2023 was another year of good performance for BioNTech. We have maintained our leading position in the COVID-19 vaccine market which lays the foundation for establishing a sustainable respiratory vaccines business. In oncology, we have strengthened our core competencies by entering into several partnerships and have made numerous clinical advances. Today, our oncology pipeline encompasses multiple candidates in mid- and late-stage clinical development, including investigational ADCs, mRNA vaccines and innovative immunotherapies,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Our goal is to achieve product approvals in ten oncological indications by 2030 and with this improve the treatment options for patients around the globe.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX:
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
- Novavax (NASDAQ:NVAX) Remains Highly Speculative, Post-Pandemic
- Autolus Therapeutics price target raised to $10 from $9 at Truist
- Options Volatility and Implied Earnings Moves This Week, March 18 – March 21, 2024
- BNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?